HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The impact of the lymph node ratio is greater than traditional lymph node status in stage III colorectal cancer patients.

AbstractBACKGROUND:
The prognostic value of nodal status in colorectal cancer (CRC) patients may be influenced by the total number of lymph nodes (LNs) harvested. This study evaluates the impact of LN ratio (LNR) on CRC patients' outcome.
METHODS:
A total of 612 stage III CRC patients who underwent curative-intent surgery between 2004 and 2008 were enrolled. The measured end point was postoperative disease-free survival (DFS) and overall survival (OS).
RESULTS:
The metastatic LN numbers were significantly higher in patients with more than 12 LN harvested (4.6 ± 5.81 vs. 2.7 ± 1.97, P < 0.001). The mean LNR was 22.9 ± 20 % (range = 2-100 %, median = 16.7 %). As the cutoff value of LNR was set above 17 %, the impact of the LNR on 5-year DFS became statistically significant. In univariate analysis, the 5-year DFS and OS for patients with high-LNR tumors was 54.4 and 57.3 %, respectively, significantly lower than those for patients with low-LNR tumors (72.8 and 76.4 %; P < 0.001). In multivariate analysis, the independent factors affecting the 5-year DFS and OS were tumor depth, carcinoembryonic antigen level, and LNR.
CONCLUSION:
The LNR, set at the median value or 17 %, could be an independent prognostic factor for stage III CRC patients.
AuthorsYen-Jung Lu, Pei-Ching Lin, Chun-Chi Lin, Huann-Sheng Wang, Shung-Haur Yang, Jeng-Kai Jiang, Yuan-Tzu Lan, Tzu-Chen Lin, Wen-Yi Liang, Wei-Shone Chen, Jen-Kou Lin, Shih-Ching Chang
JournalWorld journal of surgery (World J Surg) Vol. 37 Issue 8 Pg. 1927-33 (Aug 2013) ISSN: 1432-2323 [Electronic] United States
PMID23609344 (Publication Type: Journal Article)
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Colorectal Neoplasms (pathology)
  • Disease-Free Survival
  • Female
  • Humans
  • Lymph Nodes (pathology)
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: